Last reviewed · How we verify
AGMB-129
AGMB-129 is an anti-CD47 monoclonal antibody.
AGMB-129 is an anti-CD47 monoclonal antibody. Used for Treatment of various cancers.
At a glance
| Generic name | AGMB-129 |
|---|---|
| Sponsor | Agomab Spain S.L. |
| Drug class | monoclonal antibody |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AGMB-129 works by binding to CD47, a protein that sends a 'do not eat' signal to macrophages, thereby inhibiting tumor cell evasion from the immune system.
Approved indications
- Treatment of various cancers
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease (PHASE2)
- A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants (PHASE1)
- Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants (PHASE1)
- Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGMB-129 CI brief — competitive landscape report
- AGMB-129 updates RSS · CI watch RSS
- Agomab Spain S.L. portfolio CI